Percheron Therapeutics Limited
PERCF
Other OTC0.00
USD
- -
- -
ISIN
AU0000317281
Return %
Stock
S&P500
1Y
-50.00
22.23
3Y
-96.00
69.34
5Y
-98.57
73.59
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- James Stuart Garner
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Collins Place Melbourne VIC Australia 3000
- IPO Date
- Sep 8, 2009
- Website
- percherontx.com
- Similar Companies
- Business
- Percheron Therapeutics Limited engages in the research and development of antisense therapeutics for rare diseases, with ATL1102 (an antisense inhibitor of CD49d) in late-stage development for Duchenne muscular dystrophy, limb girdle muscular dystrophy type R2, multiple sclerosis, asthma and other inflammatory indications; ATL1103 (Atesidorsen), an oligonucleotide targeting growth hormone receptor, completes Phase II trials and aims to reduce insulin-like growth factor I and address diseases linked to excessive growth hormone action. The company, formerly Antisense Therapeutics Limited, changes its name to Percheron Therapeutics Limited in December 2023 and remains headquartered in Melbourne, Australia, with a focus on translational research and clinical development across its portfolio. Percheron operates primarily in Australia, with pipeline and collaborations extending into international partnerships and potential Regional or global clinical programs. MANDATORY - Main Products and Services: ATL1102 (CD49d antisense inhibitor) across Duchenne muscular dystrophy, limb girdle muscular dystrophy R2, multiple sclerosis, asthma and inflammatory indications; ATL1103 (Atesidorsen), growth hormone receptor antisense oligonucleotide for disorders of excessive growth hormone action; research and development services focused on antisense therapeutic discovery, preclinical validation, and Phase II/IIb/III clinical development readiness; potential companion diagnostic support and regulatory strategy services related to antisense therapy programs. Latest Major Company Changes: Name change from Antisense Therapeutics Limited to Percheron Therapeutics Limited in December 2023; advances in ATL1102 clinical development including Phase IIa progression for DMD and MS indications; ongoing Phase II trial activity for ATL1103 (Atesidorsen) addressing acromegaly and related growth hormone axis disorders; ongoing business development to pursue partnerships and potential acquisitions to accelerate pipeline progression; strategic shift toward rare disease antisense platform with emphasis on targeted inflammatory and endocrine disorders; potential reorganizations to strengthen governance and research focus following name transition. Additional Context: Industry and segments: biotechnology; antisense therapeutics; clinical development; rare diseases; inflammatory and endocrine disorders. Target markets include specialty healthcare providers, academic medical centers, and pharmaceutical partnering organizations seeking antisense therapies for neuromuscular, inflammatory, and endocrine conditions. Geographic operations center in Australia (headquarters in Melbourne) with clinical programs and collaborations potentially extending to international sites as development progresses. Subsidiaries or parent relationships: operating as a standalone biotechnology company; previously associated with Antisense Therapeutics Limited branding; no explicit parent company disclosed within current public disclosures.